PrEP Eligibility and Interest Among Clinic- and Community-Recruited Young Black Women in Atlanta, Georgia, USA

Author(s): J.M. Sales*, R.J. Steiner, J.L. Brown, A. Swartzendruber, A.S. Patel, A.N. Sheth.

Journal Name: Current HIV Research

Volume 16 , Issue 3 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Atlanta has been identified as an HIV “hot spot” for Black women and ranks 5th in the US with new infections. Yet little is known about PrEP eligibility or interest among young Black women in Atlanta.

Methods: A convenience sample of 1,261 Black women (ages 14-24 years) were recruited from two settings: community venues and sexual health clinics. They provided self-reported sexual behavior data and specimens for laboratory testing for chlamydia (CT) and gonorrhea (GC) infections. For each woman, the number of key self-reported behavioral HIV risk factors was calculated (0-6 factors for the clinic sample, 0-3 factors for the community sample). A single item assessed PrEP interest in the community sample only.

Results: Bacterial STI positivity, an indicator for PrEP eligibility, was 20.5% (17.1% CT, 6.3% GC) and 20.9% (18.8% CT, 5.2% GC) for the clinic and community samples, respectively. Of the 144 STI positive women from the clinic sample, 20.1% reported no behavioral risk indicators and 47.2% reported > 2 behavioral indicators. Of the 117 STI positive women from the community sample, 21.4% reported no behavioral risk indicators. 60.7% of the community sample reported they would be likely or very likely to use PrEP if available.

Conclusion: Young Black women in Atlanta, whether sampled from community or sexual health settings, are at substantial risk for HIV infection and meet several PrEP eligibility criteria. Scaling up PrEP among women in Atlanta could have significant implications for HIV in this high burden region.

Keywords: PrEP, women, Black or African American, United States, chlamydia, gonorrhea.

[1]
Hess KL, Hu X, Lansky A, Mermin J, Hall HI. Lifetime risk of a diagnosis of HIV infection in the United States. Annals Epidemiol 2017; 1; 27(4): 238-43.
[2]
Centers for Disease Control and Prevention (CDC). Diagnoses of HIV infection in the United States and dependent areas, 2016 [Internet]. HIV Surveillance Report; 2017 [cited 2018 Jul 23]. Report No.: 28. Available from: http://www.cdc.gov/hiv/library/ reports/ surveillance/
[3]
Centers for Disease Control and Prevention (CDC). Diagnoses of HIV infection in the United States and dependent areas, 2014 [Internet]. HIV Surveillance Report; 2015 [cited 2018 Jul 23]. Report No.: 26. Available from: http://www.cdc.gov/hiv/library/ reports/ surveillance/
[4]
Centers for Disease Control and Prevention (CDC). CDC Issue Brief: HIV in the Southern United States [Internet]. 2016 [cited 2018 Jul 23]. Available from: https://www.cdc.gov/hiv/pdf/ policies/cdc-hiv-in-the-south-issue-brief.pdf
[5]
AIDSVu. AIDSVu Annual Release of New Maps and Resources Emory University, Rollins School of Public Health; 2017 Jun 20 [cited 2018 Jul 23]. Available from: https://aidsvu.org/launch2017/
[6]
Sheth AN, Rolle CP, Gandhi M. HIV pre-exposure prophylaxis for women. J Virus Erad 2016; 2(3): 149.
[7]
Siegler AJ, Mouhanna F, Giler RM, et al. Distribution of active PrEP prescriptions and the PrEP-to-need ratio, US, Q2 2017. Abstract presented at 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018); Boston, MA 2018.
[8]
.S. Department of Health and Human Services. FDA approves first drug for reducing the risk of sexually acquired HIV infection. 2012. Available from: https://aidsinfo.nih.gov/news/1254/fda-approves-first-drug-for-reducing-the-risk-of-sexually-acquired-hiv-infection
[9]
Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363(27): 2587-99.
[10]
Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367(5): 399-410.
[11]
Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367(5): 423-34.
[12]
Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, doubleblind, placebo-controlled phase 3 trial. Lancet 2013 15; 381(9883): 2083-90.
[13]
Baeten J, Heffron R, Kidoguchi L, et al. Near elimination of HIV transmission in a demonstration project of PrEP and ART. Abstract #24 presented at Conference on Retroviruses and Opportunistic Infections; 2015 February 23-26; Seattle, WA, USA.
[14]
Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infec Dis 2015 1; 61(10): 1601-3.
[15]
Liu AY, Cohen SE, Vittinghoff E, et al. Preexposure prophylaxis for HIV infection integrated with municipal-and community-based sexual health services. JAMA Intern Med 2016; 1 76(1): 75-84.
[16]
Delaney KP, Sanchez T, Bowles K, Oraka E, DiNenno E, Sullivan P. Awareness and use of PrEP appear to be increasing among internet samples of US MSM. Abstract #889 presented at: Conference on Retroviruses and Opportunistic Infections; 2016 February 22- 25; Boston, MA, USA.
[17]
Young I, McDaid L. How acceptable are antiretrovirals for the prevention of sexually transmitted HIV?: A review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention. AIDS Behav 2014; 18(2): 195-216.
[18]
Edelstein Z, Mensah N, Scanlin K, Cutler B, Myers J. Awareness of HIV prevention innovations among women of color in NYC: HIV self-tests and pre-exposure prophylaxis (PrEP). Presented at 142nd APHA Annual Meeting and Exposition; 15-19 November 2014; New Orleans, LA, USA.
[19]
Doblecki-Lewis S, Lester L, Schwartz B, Collins C, Johnson R, Kobetz E. HIV risk and awareness and interest in pre-exposure and post-exposure prophylaxis among sheltered women in Miami. Int J STD AIDS 2016; 27(10): 873-81.
[20]
Walters SM, Reilly KH, Neaigus A, Braunstein S. Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention. Harm Reduct J 2017; 14(1): 40.
[21]
Collier KL, Colarossi LG, Sanders K. Raising awareness of pre-exposure prophylaxis (PrEP) among women in New York City: community and provider perspectives. J Health Commun 2017; 22(3): 183-9.
[22]
Auerbach JD, Kinsky S, Brown G, Charles V. Knowledge, attitudes and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care and STDs 2015; 29(2): 102-10.
[23]
Smith DK, Van Handel M, Wolitski RJ, et al. Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. MMWR Morb Mortal Wkly Rep 2015; 64(46): 1291-5.
[24]
Mera R, McCallister S, Palmer B, Mayer G, Magnuson D, Rawlings K. Truvada for HIV pre-exposure prophylaxis (PrEP) utilization in the United States: 2013-2015. Abstract TUAX0105LB presented at the 21st International AIDS Conference; 2016 July 18-22; Durban, South Africa.
[25]
Bush S, Magnuson D, Rawlings M, Hawkins T, McCallister S, Mera Giler R. Racial characteristics of ftc/tdf for pre-exposure prophylaxis users in the us. Abstract 2651 presented at the American Society for Microbiology (ASM Microbe) 2016; 2016 June 16-20, 2016. Boston, MA, USA.
[26]
Centers for Disease Control and Prevention (CDC). US Public Health Service Preexposure prophylaxis for the prevention of HIV infection in the United States-2014: A clinical practice guideline [Internet]. 2014 May 31 [cited 2018 Jul 23]. Available from: https://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf
[27]
Adimora A, et al. New approaches for HIV prevention trials. Clin Infect Dis 2017; 65: 324.
[28]
Beymer MR, Weiss RE, Sugar CA, et al. Are centers for disease control and prevention guidelines for preexposure prophylaxis specific enough? formulation of a personalized hiv risk score for pre-exposure prophylaxis initiation. Sex Trans Dis 2017; 44(1): 48-56.
[29]
Aaron E, Blum C, Seidman D, et al. Delivery of HIV preexposure prophylaxis for women in the United States. AIDS Patient Care STDs 2018; 32(1): 16-23.
[30]
Willie TC, Stockman JK, Overstreet NM, Kershaw TS. Examining the impact of intimate partner violence type and timing on pre-exposure prophylaxis awareness, interest, and coercion. AIDS Behav 2018; 22(4): 1190-200.
[31]
DiClemente RJ, Wingood GM, Sales JM, et al. Efficacy of a telephone-delivered sexually transmitted infection/human immunodeficiency virus prevention maintenance intervention for adolescents: a randomized clinical trial. JAMA Pediatr 2014; 168(10): 938-46.
[32]
Curran TM, Monahan JL, Samp JA, Coles VB, DiClemente RJ, Sales J. Sexual risk among African American women: Psychological factors and the mediating role of social skills. Commun Q 2016; 64(5): 536-52.
[33]
Collier KL, Colarossi LG, Sanders K. A PrEP information and self-screening tool for women. AIDS Educ Prev 2018; 30(1): 13-25.
[34]
Patel A, Goparaju L, Sales JM, et al. Predictors of PrEP eligibility among at−risk women in the Southern United States. Poster presented at: Annual CROI meeting; 2018 March; Boston, MA, USA.
[35]
Corneli A, Perry B, Agot K, Ahmed K, Malamatsho F, Van Damme L. Facilitators of adherence to the study pill in the FEM-PrEP clinical trial. PLoS One 2015; 10(4): e0125458.
[36]
van der Straten A, Stadler J, Luecke E, et al. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE‐C qualitative study in Johannesburg, South Africa. J Int AIDS Soc 2014; 17: 19146.
[37]
Seidman D, Carlson K, Weber S, Witt J, Kelly PJ. United States family planning providers’ knowledge of and attitudes towards preexposure prophylaxis for HIV prevention: a national survey. Contraception 2016; 93(5): 463-9.
[38]
Frost JJ, Gold RB, Bucek A. Specialized family planning clinics in the United States: why women choose them and their role in meeting women’s health care needs. Womens Health Issues 2012; 22(6): e519-25.
[39]
US women & PrEP working group position statement [Internet]. Sister Love; 2015 [cited 2018 Jul 23]. Available from: http://www.sisterlove.org/wp-content/uploads/2015/11/US-Women-and-PrEP-Updated-Statement-_Final2-1.pdf 2015
[40]
Seidman D, Weber S. Integrating preexposure prophylaxis for human immunodeficiency virus prevention into women’s health care in the United States. Obstet Gynecol 2016; 128(1): 37-43.
[41]
Gavin L, Pazol K. Update: providing quality family planning services - recommendations from cdc and the u.s. office of population affairs. MMWR Morb Mortal Wkly Rep 2016; 65(9): 231-4.
[42]
Office of Population Affiars (OPA). Funding History [Internet]. U.S. Department of Health and Human Services; 2017 Feb 21 [cited 2018 Jul 23]. Available from https://www.hhs.gov/opa/title-x-family-planning/about-title-x-grants/funding-history/index.html
[43]
Fowler C I, Gable J, Wang J, Lasater B. Family planning annual report: 2016 national summary. Research Triangle Park, NC: RTI International, 2017 August. https://www.hhs.gov/opa/ sites/default/ files/title-x-fpar-2016-national.pdf Accessed June 18, 2018.
[44]
Mugo NR, Ngure K, Kiragu M, Irungu E, Kilonzo N. PrEP for Africa: What we have learnt and what is needed to move to program implementation. Curr Opin HIV AIDS 2016; 11(1): 80.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 3
Year: 2018
Page: [250 - 255]
Pages: 6
DOI: 10.2174/1570162X16666180731143756

Article Metrics

PDF: 21
HTML: 7